HomeCompareSHTDY vs FCPT

SHTDY vs FCPT: Dividend Comparison 2026

SHTDY yields 3.61% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FCPT wins by $27.1K in total portfolio value
10 years
SHTDY
SHTDY
● Live price
3.61%
Share price
$13.04
Annual div
$0.47
5Y div CAGR
-17.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.0K
Annual income
$59.46
Full SHTDY calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — SHTDY vs FCPT

📍 FCPT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSHTDYFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SHTDY + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SHTDY pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SHTDY
Annual income on $10K today (after 15% tax)
$306.48/yr
After 10yr DRIP, annual income (after tax)
$50.54/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, FCPT beats the other by $4,858.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SHTDY + FCPT for your $10,000?

SHTDY: 50%FCPT: 50%
100% FCPT50/50100% SHTDY
Portfolio after 10yr
$35.5K
Annual income
$2,917.37/yr
Blended yield
8.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

SHTDY
No analyst data
Altman Z
3.9
Piotroski
7/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SHTDY buys
0
FCPT buys
0
No recent congressional trades found for SHTDY or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSHTDYFCPT
Forward yield3.61%6.05%
Annual dividend / share$0.47$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-17.4%15.8%
Portfolio after 10y$22.0K$49.1K
Annual income after 10y$59.46$5,775.28
Total dividends collected$1.5K$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: SHTDY vs FCPT ($10,000, DRIP)

YearSHTDY PortfolioSHTDY Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$10,998$297.83$11,401$700.92$403.00FCPT
2$12,021$252.85$13,064$864.84$1.0KFCPT
3$13,075$213.35$15,051$1,072.48$2.0KFCPT
4$14,170$179.15$17,442$1,337.22$3.3KFCPT
5$15,311$149.87$20,340$1,677.08$5.0KFCPT
6$16,508$125.02$23,880$2,116.57$7.4KFCPT
7$17,768$104.05$28,241$2,689.36$10.5KFCPT
8$19,098$86.45$33,660$3,442.07$14.6KFCPT
9$20,507$71.73$40,456$4,439.95$19.9KFCPT
10$22,002$59.46$49,063$5,775.28$27.1KFCPT

SHTDY vs FCPT: Complete Analysis 2026

SHTDYStock

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Full SHTDY Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this SHTDY vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SHTDY vs SCHDSHTDY vs JEPISHTDY vs OSHTDY vs KOSHTDY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.